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Abstract
Background: Mutations in the gene encoding human myocilin (MYOC) have been shown to cause
juvenile- and adult-onset glaucoma. In addition, myocilin has been associated with glucocorticoid-
induced ocular hypertension and steroid-induced glaucoma. To better understand the role myocilin
plays in steroid-induced glaucoma and open-angle glaucoma, we examined rabbit myocilin for use
in the rabbit animal model of steroid-induced glaucoma.
Results: We have cloned the rabbit ortholog of human MYOC. Rabbit MYOC consists of three
exons and an open reading frame encoding a 490 amino acid, 54,882-Da protein, which is 14 amino
acids shorter at the N-terminus than human myocilin but 84% identical overall. Rabbit myocilin
migrates as a single electrophoretic band, vs. double-banded human myocilin, by SDS-PAGE/
immunoblot analysis. We determined that the differential migration exhibited is due to an N-
glycosylation site that is present in human (Asn57), monkey and mouse myocilin but absent in rabbit
(Ser43), rat and bovine myocilin. Rabbit myocilin is secreted in vitro in trabecular meshwork cell
culture and in vivo in aqueous humor. Secretion of human myocilin is shown to be dependent on
the signal peptide and independent of the extra 14 amino acids not found in rabbit myocilin. Many
of the amino acids in myocilin that are mutated in glaucoma patients are conserved across species.
Conclusion: We have cloned the rabbit MYOC cDNA and determined that rabbit myocilin is
secreted but not N-linked glycosylated. Knowledge of the rabbit MYOC cDNA sequence will
facilitate future studies in the rabbit animal model examining the role of myocilin in steroid-induced
glaucoma and the gain-of-function hypothesis in open-angle glaucoma.
Background
Mutations in MYOC have been shown to be causative for
primary open angle glaucoma (POAG) [1–3]. Glucocorti-
coids have been implicated in ocular hypertension and
glaucoma due to increased plasma cortisol levels [4,5] and
altered cortisol metabolism [6,7] in POAG patients and
from the increased risk of developing POAG in steroid-re-
sponsive patients [8,9]. Myocilin has been shown to be
upregulated in glucocorticoid-treated human trabecular
meshwork (TM) cells [10,11], and there is variable
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evidence for increased MYOC expression in glaucomatous
individuals [12–14]. In addition, glaucoma patients have
a higher chance of responding to steroids than non-glau-
comatous individuals. However, an extensive study of
mutations in the proximal promoter and coding region of
MYOC  found no sequence polymorphisms associated
with steroid responsiveness [15].
Myocilin has been shown to be secreted both in human
TM cell cultures and in vivo in aqueous humor (AH) [12].
Glaucomatous mutations, however, alter myocilin Triton
solubility [16] and prevent myocilin from being secreted
[12]. The glycosylation status of myocilin is somewhat
controversial. Several groups have shown that myocilin is
glycosylated [10,16–21] whereas one group suggests that
myocilin is not glycosylated [22]. In our hands, both an
N-linked glycosylated (≈57-kDa) and unglycosylated
(≈55-kDa) form of myocilin is detected in TM cell culture
media [17] and aqueous humor [12]. The basis for both
secretion and N-linked glycosylation of myocilin is part of
the focus of this paper.
Rabbits have been successfully used as a model of gluco-
corticoid-induced ocular hypertension [23–27]. In order
to study the association of MYOC gene expression with
steroid-induced ocular hypertension, it will be helpful to
know the sequence of rabbit myocilin. We report here the
cloning, sequence comparison and expression analysis of
rabbit MYOC. We show that an N-terminal signal peptide
is necessary for myocilin secretion and we identify the N-
linked glycosylation site found in human but not rabbit
myocilin.
Results
Characterization of Rabbit MYOC
We have cloned a 2-kb cDNA for rabbit MYOC that en-
codes a 490 amino acid, 55-kDa protein with a calculated
pI of 5.25 (Fig. 1). Rabbit myocilin amino acid sequence
is 84% identical to human myocilin [28] and highly ho-
mologous across species (Table 2) with an overall 64%
homology. Rabbit myocilin is 14 amino acids shorter at
the N-terminus than human myocilin and the same
length as monkey [15], mouse [29,30], and bovine [31]
myocilin (Fig. 2). As in all myocilin orthologs cloned to
date, rabbit myocilin contains a leucine zipper motif (aa
103 to 152) (Fig. 2). A potential peroxisomal targeting sig-
nal is encoded on the C-terminus (SKI, aa 488–490). Un-
like human, monkey and mouse myoclin, rabbit myocilin
does not contain a consensus N-linked glycosylation site
(N-X-S/T; human, aa 57–59; monkey, aa 43–45; mouse,
aa 43–45) (Fig. 2). The nucleotide sequence for rabbit
MYOC reported in this manuscript has been submitted to
GenBank (AY191317).
Secretion of Rabbit MYOC
Rabbit, monkey, mouse and bovine myocilin open read-
ing frames begin at amino acid 15 relative to human my-
ocilin. The function, if any, of the extra N-terminal 14 aa
encoded by human myocilin is not presently known. Rat
myocilin also contains an extra 13 aa N-terminal se-
quence [32]. To determine if rabbit myocilin is secreted
despite the absence of the additional human-like N-termi-
nal 14 aa, we examined rabbit aqueous humor. We were
able to detect myocilin in rabbit aqueous humor (Fig. 3A).
This suggests that the human N-terminal 14 aa is dispen-
sible for secretion and that the rabbit myocilin sequence
is sufficient to direct secretion.
Next we created a human myocilin expression construct
where the N-terminal 14aa were deleted (pcDNA3.hMY-
OC.∆N14) forcing translation to begin at the second me-
thionine codon (Fig. 2). GTM66 cells were chosen for this
study based on their ability to grow and transfect well and
are a glaucomatous TM cell line derived from a 92-year-
old female donor [11,17]. Transfection of GTM66 cells
with the N-terminal deletion mutant resulted in a distri-
bution pattern similar to wild-type human myocilin (Fig.
3B). The fact that we see no discernable difference in the
relative mobility between transfected human wild-type
myocilin and 14 amino acid amino-terminal deleted my-
ocilin (Fig. 3B) and human vs. monkey myocilin in AH
(Fig. 3A) may be due to the use of small format gels or
possibly to the usage of the second N-terminal methio-
nine by the cell for synthesizing human myocilin, making
human and monkey molecular weights comparable.
Nonetheless, an N-terminal signal peptide is likely neces-
sary for directing synthesis of myocilin, via the ER-Golgi
pathway, for secretion outside the cell. To determine what
actually constitutes the signal sequence for myocilin, we
conducted an analysis of signal peptide cleavage sites us-
ing the Center for Biological Sequence Analysis SignalP
v1.1 Database http://www.cbs.dtu.dk/services/SignalP/. A
signal peptide cleavage site was predicted to exist between
rabbit aa 18 and 19 (human aa 32 and 33) [33]. We direct-
ly tested the importance of the signal peptide in myocilin
secretion by replacing the first 32 aa of human myocilin
with a single methionine (pcDNA3.hMYOC.∆N32).
Transfection of GTM66 cells with pcDNA3.hMYOC.∆N32
resulted in intracellular but not extracellular myocilin dis-
tribution (Fig. 3B). This is the result expected if the signal
peptide were necessary for secretion. This suggests that the
first 18 aa of rabbit myocilin may function as a signal pep-
tide and are necessary for myocilin secretion.
Myocilin Glycosylation
Human myocilin has been shown to migrate as a 55/57-
kDa doublet by SDS-PAGE/immunoblot analysis [10–
12,16,17]. The modification accounting for thisBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/5
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Figure 1
Rabbit MYOC Sequence. Nucleotide and deduced amino acid sequence of rabbit MYOC cDNA. Open reading frame nucle-
otides are shown in bold. Encoded amino acids are shown by single letter code and the stop codon is indicated with an aster-
isk. Numbers to the left indicate nucleotide position. The consensus polyadenylation signal (AATAAA) is underlined.
    1 GAAGCCTCACCCAGCCTCTGCACCAAGGTTTTTCCCTGCACATTGCTGCAGCTGCAGACC
M  P  A  V  Q  L  L  L  L  A  G  L  V  W  G  A  G  A  R ·
   61 CACAATGCCAGCTGTCCAGCTGCTGCTTCTGGCCGGCCTGGTGTGGGGCGCTGGGGCCAG
· T  A  Q  L  R  K  A  N  D  R  S  G  R  C  Q  Y  T  F  S  V ·
  121 GACAGCCCAACTCCGAAAGGCAAATGACCGGAGTGGCCGGTGCCAGTACACCTTCAGCGT
· A  S  P  S  E  S  S  C  P  E  Q  G  Q  T  M  S  A  I  Q  D ·
  181 AGCCAGCCCCAGTGAATCCAGCTGCCCCGAGCAGGGCCAGACCATGTCAGCCATCCAGGA
· L  Q  R  D  S  S  T  Q  R  A  D  L  E  S  T  K  A  R  L  S ·
  241 CCTCCAGAGAGACAGCAGTACCCAGCGTGCAGACCTGGAGTCCACCAAAGCCCGGCTCAG
· S  L  E  S  L  L  H  R  L  T  L  A  Q  T  S  G  P  Q  E  I ·
  301 TTCCCTGGAGAGCCTCCTCCACCGGTTGACCTTGGCACAGACCAGCGGACCCCAGGAGAT
· Q  E  E  L  Q  K  E  L  G  T  L  R  R  E  R  D  Q  L  E  S ·
  361 CCAGGAGGAATTGCAGAAGGAGCTGGGCACCCTGAGGAGAGAGCGGGACCAGCTGGAAAG
· Q  T  R  E  L  E  A  A  Y  S  N  L  L  R  D  K  S  A  L  E ·
  421 CCAAACCAGGGAGCTGGAGGCAGCCTATTCCAACCTCCTCCGAGACAAGTCAGCTCTGGA
· E  E  K  R  R  L  M  Q  E  N  E  D  L  A  R  R  L  E  S  S ·
  481 GGAAGAGAAGAGGCGCTTGATGCAGGAGAATGAGGACCTGGCCAGGAGGTTGGAGAGCAG
· S  Q  E  V  A  R  L  A  R  G  Q  C  P  Q  A  R  D  T  S  Q ·
  541 CAGCCAGGAGGTGGCGAGGCTGGCAAGGGGCCAGTGTCCCCAGGCCCGGGACACCTCTCA
· D  V  P  A  G  S  R  E  A  S  Q  W  N  L  D  T  L  A  F  Q ·
  601 GGATGTGCCTGCAGGCTCCAGGGAAGCTTCTCAATGGAATTTGGACACTTTGGCCTTCCA
· E  L  K  S  E  L  T  E  V  P  A  S  R  I  L  K  E  N  P  P ·
  661 GGAGCTGAAGTCGGAGTTAACTGAAGTTCCTGCTTCCCGAATCTTGAAGGAGAACCCACC
· V  L  P  R  G  E  E  G  D  N  G  C  G  E  L  V  W  V  G  Q ·
  721 TGTTCTCCCCAGGGGTGAAGAGGGAGACAACGGATGTGGGGAACTAGTTTGGGTAGGACA
· P  V  T  L  R  T  A  E  T  I  T  G  K  Y  G  V  W  M  R  D ·
  781 GCCTGTCACTCTGAGGACAGCCGAAACTATCACTGGCAAGTATGGCGTGTGGATGAGAGA
· P  K  P  T  S  P  H  T  Q  E  T  T  W  R  I  D  T  V  G  T ·
  841 CCCCAAGCCCACATCCCCCCACACCCAGGAGACCACGTGGAGAATCGACACGGTCGGCAC
· D  I  R  Q  V  F  E  Y  D  R  I  S  Q  F  V  Q  G  Y  P  S ·
  901 CGACATCCGCCAGGTCTTTGAGTATGACCGCATCAGCCAGTTTGTGCAGGGGTACCCTTC
· K  V  Y  V  L  P  R  S  L  E  S  T  G  A  V  V  Y  A  G  S ·
  961 GAAGGTGTACGTGCTGCCCAGGTCGCTGGAGAGCACAGGTGCCGTGGTCTACGCAGGCAG
· L  Y  F  Q  G  A  G  S  R  T  V  I  R  F  E  L  N  T  E  T ·
 1021 CCTCTACTTCCAGGGTGCTGGGTCCAGAACTGTGATCAGGTTTGAGCTGAACACTGAGAC
· V  K  A  E  K  E  I  P  G  A  G  Y  R  G  Q  F  P  Y  S  W ·
 1081 AGTGAAGGCCGAGAAGGAAATCCCTGGAGCCGGCTACCGTGGGCAGTTTCCATATTCTTG
· G  G  Y  T  D  I  D  L  A  V  D  E  T  G  L  W  V  I  Y  S ·
 1141 GGGTGGCTACACGGACATTGACCTGGCTGTGGACGAGACCGGTCTCTGGGTCATCTACAG
· T  E  E  A  R  G  A  I  V  L  S  K  L  N  P  E  N  L  E  L ·
 1201 CACCGAGGAGGCCAGAGGTGCCATTGTCCTCTCCAAATTGAACCCAGAGAATCTGGAACT
· E  K  T  W  E  T  N  I  R  K  Q  S  V  A  N  A  F  I  I  C ·
 1261 TGAAAAAACCTGGGAGACCAATATCCGTAAGCAGTCGGTTGCCAACGCCTTCATCATCTG
· G  T  L  Y  T  V  S  S  Y  S  S  A  D  A  T  V  N  F  A  Y ·
 1321 TGGCACCTTGTACACTGTTAGCAGCTACTCCTCGGCAGATGCCACCGTCAACTTCGCTTA
· D  T  G  T  G  I  S  K  P  L  A  I  P  F  K  N  R  Y  K  Y ·
 1381 TGACACGGGCACTGGGATCAGCAAGCCCTTGGCCATCCCATTCAAGAACCGCTACAAATA
· S  S  M  I  D  Y  N  P  L  E  R  K  L  F  A  W  D  S  F  N ·
 1441 CAGCAGCATGATCGACTACAACCCTCTGGAGAGGAAGCTCTTTGCCTGGGACAGCTTCAA
· M  V  T  Y  D  I  K  L  S  K  I  *
 1501 CATGGTCACCTATGACATCAAGCTGTCCAAGATTTAACAGCCTCCAGGTGCTACCAGCAA
 1561 TGGCAGAAAGACGATGCTCAGGGCTCCTGGGGAGAAGATGAGGAGGGCCAGCCAGCTGGG
 1621 GACTGCATGGCTTCTCTCTGCTTTCCAAGCTTGCATTAATCCAGATGGATGTATGCGGTC
 1681 ACCATCAGACTGTGCAGCGATTAGCAATTAGTACCATGCAGTACTTAGAGAATTTCTTAT
 1741 TGTAGTAGATATTCTTTTCTTCTTCTGTCTGGTTCATGAAATAGTTCATATTTTCCAGTG
 1801 ATTTGAGGCAAAAGCTATAAAGTAACATGGTAGTTACTTCATGTTATATGGTTCCCATAA
 1861 GCCACCATCAAGAGCAGGATTTCTAAAGAAACAACAGTAGCTCTTGTGGCCAGCACTGAA
 1921 CCTCTGTAGGATGCATTTGCTACAGTTGACTTCTAATACTTTAGGTAGAACTCAGTTTGA
 1981 TATTACATAACTTTCTGCTCTATGAAATAAAATTATCTTGCACAACAAAAAAAAAAAGAA
 2041 AAAAGBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/5
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Figure 2
Alignment of myocilin orthologs. Alignment of rabbit, human, monkey, mouse, rat, and bovine myocilin amino acid 
sequences. Identical amino acids are shaded and missing amino acids are indicated with a dash. The 14 amino acid deletion in 
human MYOC plasmid pcDNA3.hMYOC.∆N14 is underlined. The putative myocilin signal peptide is boxed. Location of the 
predicted N-linked glycosylation site (human myocilin Asn57) is indicated with a 'n'. Locations of predicted O-linked glycosyla-
tion sites are marked with an 'o'. The leucine zipper motif is marked by dots. Disease-causing mutations identified based on 
experimental data and statistical arguments with glaucoma family pedigrees and documented in the Human Gene Mutation 
Database http://uwcmml1s.uwcm.ac.uk/uwcm/mg/search/5584221.html are indicated with a 'x'. GenBank accession numbers 
are as follows: rabbit, AY191317; human, NM_000261; monkey, AY190128, AY190129, AY190130; mouse, AF039869; rat, 
AF093567; bovine, AB027758.
                                                            n o
Rabbit MYOC    (1) --------------MPAVQLLLLAGLVWGAGARTAQLRKANDRSGRCQYTFSVASPSESS
 Human MYOC    (1) MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESS
Monkey MYOC    (1) --------------MPAVQLLLLACPVWDVGARTAQLRKANDRSGRCQYTFSVASPNESS
 Mouse MYOC    (1) --------------MPALHLLFLACLVWGMGARTAQFRKANDRSGRCQYTFTVASPNESS
   Rat MYOC    (1) -MPSCARCCSCGPKMPALQLLFLACLVWGMGARTAQFRKANDRSGRCQYTFTVASPSESS
Bovine MYOC    (1) --------------MPAVQLLLLACLLGGVGARTAQFQKANDRSGRCQYTFSVASPSESS
                                      o                           o
Rabbit MYOC   (47) CPEQGQTMSAIQDLQRDSSTQRADLESTKARLSSLESLLH-RLTLAQTSGPQEIQEELQK
 Human MYOC   (61) CPEQSQAMSVIHNLQRDSSTQRLDLEATKARLSSLESLLH-QLTLDQAARPQETQEGLQR
Monkey MYOC   (47) CPEQSQAMSVIHNLQKDSSTQRLDLEATKARLSSLESLLHHQLTLDRAAGPQETPEGLQR
 Mouse MYOC   (47) CPREDQAMSAIQDLQRDSSIQHADLESTKARVRSLESLLH-QMTLGRVTGTQEAQEGLQG
   Rat MYOC   (60) CPREDQAMSAIQDLQRDSSIQHADLESTKARVRSLESLLH-QMTSGGVTGTQEVQEGLQG
Bovine MYOC   (47) CPEQGQAMLAIQELQRDSSEQRATLESTKARLSSLEALLH-RLTSGQPAGPLETHQGLQR
Rabbit MYOC  (106) ELGTLRRERDQLESQTRELEAAYSNLLRDKSALEEEKRRLMQENEDLARRLESSSQEVAR
 Human MYOC  (120) ELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVAR
Monkey MYOC  (107) ELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVAR
 Mouse MYOC  (106) QLGALRRERDQLETQTRDLEAAYNNLLRDKSALEEEKRQLEQENEDLARRLESSSEEVAR
   Rat MYOC  (119) QLGALRRERDQLETQTRDLEVAYNNLLRDKSALEEEKRQLEQENKDLARRLEGSSQEVAR
Bovine MYOC  (106) ELEALRREREQLETQTQELESAYSNLVRDKSALEEEKRRLQAENEDLARRLESSSQEVAS
Rabbit MYOC  (166) LARGQCPQARDTSQDVPAGSREASQWNLDTLAFQELKSELTEVPASRILKENPPVLPRGE
 Human MYOC  (180) LRRGQCPQTRDTARAVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGYLRSG
Monkey MYOC  (167) LRRGQCPQTRDTARDVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGHLQSR
 Mouse MYOC  (166) LRRGQCPSTQYPSQDMLPGSREVSQWNLDTLAFQELKSELTEVPASQILKENPSGRPRSK
   Rat MYOC  (179) LRRGQCPSTHHPSQDMLPGSREVSQWNLDTLAFQELKSELTEVPASQILK-NQSGHPRSK
Bovine MYOC  (166) LRRGQCPQAHSSSQDVPSGSREVAKWNLENMDFQELKSELTEVPASQILKESPSGHPRNE
                                                        o   o
Rabbit MYOC  (226) EGDNGCGELVWVGQPVTLRTAETITGKYGVWMRDPKPTSPHTQETTWRIDTVGTDIRQVF
 Human MYOC  (240) EGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVF
Monkey MYOC  (227) EGDNGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTRETTWRIDTVGTDVRQVF
 Mouse MYOC  (226) EGDKGCGALVWVGEPVTLRTAETIAGKYGVWMRDPKPTHPYTQESTWRIDTVGTEIRQVF
   Rat MYOC  (238) EGDKGCGVLMWVGEPVTLRTAETITGKYGVWMRDPKPTHPYTQETTWRIDTVGTGIRQVF
Bovine MYOC  (226) EGGTGCGELVWVGEPITLRTAETITGKYGVWMRDPRAAFPYTGETTWRIDTVGTDIRQVF
Rabbit MYOC  (286) EYDRISQFVQGYPSKVYVLPRSLESTGAVVYAGSLYFQGAGSRTVIRFELNTETVKAEKE
 Human MYOC  (300) EYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKE
Monkey MYOC  (287) EYDLISQFMQGYPSKVHILPRPLESTGAVVYSGNLYFQGAESRTVIRYELNTETVKAQKE
 Mouse MYOC  (286) EYSQISQFEQGYPSKVHVLPRALESTGAVVYAGSLYFQGAESRTVVRYELDTETVKAEKE
   Rat MYOC  (298) EYSQISQFEQGYPSKVHVLPQALESTGAVVYAGSLYFQGAESRTVLRYELNTETVKAEKE
Bovine MYOC  (286) EYDHIRKFTQGYPSKVHVLPRPLESTGAVVYRGSLYFQAAESRTVLRYDLRTETLKAEKE
Rabbit MYOC  (346) IPGAGYRGQFPYSWGGYTDIDLAVDETGLWVIYSTEEARGAIVLSKLNPENLELEKTWET
 Human MYOC  (360) IPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWET
Monkey MYOC  (347) IPGAGYHGQFPYSWGGYTDIDLAVDESGLWVIYSTDEAKGAIVLSKLNPENLELEQTWET
 Mouse MYOC  (346) IPGAGYHGHFPYAWGGYTDIDLAVDESGLWVIYSTEEAKGAIVLSKLNPANLELERTWET
   Rat MYOC  (358) IPGAGYHGQFPYAWGGYTDIDLAVDESGLWVIYSTEETRGAIVLSKLNPENLELESTWET
Bovine MYOC  (346) IPGAGYHGQFPYSWGGYTDIDLAVDEIGLWVIYSTEAAKGAIVLSKLNPETLELEQTWET
Rabbit MYOC  (406) NIRKQSVANAFIICGTLYTVSSYSSADATVNFAYDTGTGISKPLAIPFKNRYKYSSMIDY
 Human MYOC  (420) NIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDY
Monkey MYOC  (407) NIRKQSVANAFIICGTLYTVSSYSSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDY
 Mouse MYOC  (406) NIRKQSVANAFVICGILYTVSSYSSAHATVNFAYDTKTGTSKTLTIPFTNRYKYSSMIDY
   Rat MYOC  (418) NIRKQSVANAFVICGILYTVSSYSSVHATINFAYDTNTGISKTLTIPFKNRYKYSSMVDY
Bovine MYOC  (406) NIRKQSVANAFIICGTLYTVSSYSSPDATVNFAYDTGTGSSKALTVPFKNRYKYSSMIDY
Rabbit MYOC  (466) NPLERKLFAWDSFNMVTYDIKLSKI
 Human MYOC  (480) NPLEKKLFAWDNLNMVTYDIKLSKM
Monkey MYOC  (467) NPLEKKLFAWDNLNMVTYDIKLSKM
 Mouse MYOC  (466) NPLERKLFAWDNFNMVTYDIKLLEM
   Rat MYOC  (478) NPLERKLFAWDNFNMVTYDIKLSEM
Bovine MYOC  (466) NPLERKLFAWDNFNMVSYDIKLSRL
•
•••• •••
x
x
x x
x xx
x x xx xx x x x
xx x x x x x x x
xx x x x
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molecular weight difference is hypothesized to be due to
differential glycosylation. N-linked glycosylation sites
were predicted using the Center for Biological Sequence
Analysis NetNGlyc 1.0 Prediction Server http://
www.cbs.dtu.dk/services/NetNGlyc/. Human, monkey
and mouse myocilin contain a consensus asparagine (N)-
linked glycosylation site (NES) near the N-terminus,
whereas rabbit, rat and bovine code for SES at this posi-
tion (Fig. 2). Having a serine present at this position
would eliminate N-linked glycosylation and would be
predicted to result in a difference in relative gel mobility
between human/monkey and rabbit myocilin.
To test this hypothesis we analyzed human, monkey, and
rabbit AH myocilin side-by-side in SDS-PAGE/immunob-
lots. The anti-human myocilin antibody 129 used in these
studies (generated to human amino acids 156–
171[12,17]) cross-reacts with rabbit and monkey myoci-
lin. With human and monkey myocilin we see a clear dou-
blet, whereas rabbit myocilin migrates as a single band
with the same relative mobility as the lower band of hu-
man and monkey myocilin (Fig. 3A), suggesting that the
asparagine vs. serine amino acid difference is responsible
for the differential glycosylation.
To directly test this theory, we mutated human myocilin
amino acid 57 from Asn to Ser, as found in rabbit myoci-
lin. Media and cell lysate from transfected GTM66 cells
contained a single immunoreactive myocilin band that
migrated with the same relative mobility as the lower wt
myocilin band (Fig. 3B). This suggests that the 55/57-kDa
human myocilin doublet is due to differential glycosyla-
tion and that the site of N-linked glycosylation on human
myocilin is Asn 57.
To determine the effects of deglycosylation on myocilin,
we treated human, monkey, and rabbit AH with a cocktail
of glycosidases (N- and O-linked). Our results show that
Table 1: Rabbit and Human MYOC primers used for PCR and Cloning
Primer Sequence
Exon1F* 5'-CAGTCCCAATGAATCCAGC-3'
Exon1R 5'-CTCTCTGGTTTGGGTTTCCA-3'
5'RACE 5'-CAGCTCCTTCTGCAATTCCTCCT-3'
5'RACEnest 5'-CTTCTGCAATTCCTCCTGGATCTC-3'
3'RACE 5'-CATCCAGGACCTCCAGAGAGACAG-3'
3'RACEnest 5'-ACCTCCAGAGAGACAGTACCC-3'
P355F 5'-CTTCTCAATGGAATTTGGACACTT-3'
P356F 5'-GATGTGGGGAACTAGTTTGGGTAG-3'
P356R 5'-AGTGCGGCCGCTTAAATCTTGGACAGCTTGATGTC-3'
P357F 5'-GCAGGATCCCCAAGGTTTTTCCCTGCACATTGCTGC-3'; BamH1 underlined
P365R 5'-AGTGCGGCCGCGTTGTCTCCCTCTTCACCC-3'; Not1 underlined
P368R 5'-pCTTCCCTGGAGCCTGCAGGCACAT-3'; p indicates phosphorylation
P370R 5'-pCGTTGTCTCCCTCTTCACCCCTGG-3'; p indicates phosphorylation
P235 5'-CCCAAGCTTATGCCAGCTGTCCAGCTGCT-3'; HindIII underlined
P236 5'-CCCAAGCTTATGAGGACAGCTCAGCTCAGGAAG-3'; HindIII underlined
P237 5'-CCGCCTCAGGGTGCCCAGCT-3'; Bsu36I underlined
P316F 5'-GGCCAGTCCCAGTGAATCCAGCTGCCC-3'; Mutation underlined
P316R 5'-GGGCAGCTGGATTCACTGGGACTGGCC-3'; Mutation underlined
* Note: F, forward orientation; R, reverse orientation
Table 2: Myocilin ortholog identity comparison
Human Rabbit Monkey Mouse Rat Bovine
Human 100 84 94 80 81 80
R a b b i t 1 0 0 8 68 38 08 2
Monkey 100 82 79 82
Mouse 100 91 79
Rat 100 77
Bovine 100BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/5
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Figure 3
Rabbit MYOC expression. Western immunoblot analysis of myocilin in (A) rabbit, human, and monkey aqueous humor 
samples treated with (+) or without (-) glycosidases and in (B) GTM66 cells transfected with expression vectors encoding 
wild-type human MYOC (WT), N-terminal 14 (∆N14) or 32 (∆N32) aa deleted human MYOC, or N57S mutated human MYOC. 
I, intracellular myocilin present in the cell lysate; E, extracellular myocilin secreted into the medium. 57/55-kDa myocilin dou-
blet is indicated with arrows.
∆ ∆ ∆ ∆N32
E    I
∆ ∆ ∆ ∆N14
E   I
WT
E I
191 -
64 -
51 -
39 -
28 -
97 -
N57S
E I
64 -
51 -
39 -
97 -
Rabbit
+ -
Monkey
+ -
Human
+ -
A
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the upper band of human and monkey myocilin is elimi-
nated whereas the lower band remains unaltered (Fig.
3A). This indicates that the upper human and monkey
myocilin band is glycosylated. In addition, the single rab-
bit myocilin band shifted downward slightly with deglyc-
osylation. This may be due to removal of O-linked
glycosylation.
Discussion
We report the cloning and characterization of rabbit myo-
cilin. Rabbit myocilin is highly similar to the other myo-
cilin orthologs (Table 2) and contains a leucine zipper
motif encoded by exon 1 (Fig. 2). This conservation likely
reflects the importance of the leucine zipper motif in di-
recting protein-protein interactions [34,35]. Many amino
acid mutations encoded in the olfactomedin homology
domain of exon 3 that are known to cause glaucoma in
humans are also conserved in rabbit myocilin. In fact, all
31 amino acids (34 missense/nonsense mutations total)
for human myocilin documented in the Human Gene
Mutation Database http://uwcmml1s.uwcm.ac.uk/uwcm/
mg/search/5584221.html to cause glaucoma are con-
served in rabbit myocilin (Fig 2).
Myocilin has been shown to be secreted in vitro and in vivo
by several investigators [10–12,20,21,34,36–38]. Secreted
proteins typically contain a 16–30 aa signal sequence on
their N-terminus which directs the completion of protein
synthesis across the ER membrane. A signal peptidase
cleaves the signal sequence and the trimmed protein is
shuttled through the Golgi for secretion. We demonstrate
the functionality of the N-terminal signal peptide in di-
recting myocilin secretion. Deletion of the predicted N-
terminal signal peptide results in loss of secretion but not
intracellular appearance (Fig. 3B).
There are conflicting reports on whether myocilin is glyc-
osylated. Differential glycosylation of myocilin has been
shown in this report and by others [17,20,21] to account
for the appearance of a 55/57-kDa doublet by Western im-
munoblot analysis. In contrast, Huang et al. [22] report
that myocilin is not glycosylated. This discrepancy may be
due to technical reasons. Huang et al. did not resolve the
55/57-kDa doublet using their SDS-PAGE system and
only detected a 57-kDa human myocilin band, so any
deglycosylation (PNGase F, NANase II, and O-Glycosi-
dase) occurring would be difficult to resolve. A positive
control was not reported in their deglycosylation experi-
ment, so their conclusion that myocilin is not glycosylat-
ed may simply be due to inactive glycosidase. The lack of
glycosylation seen in the in vitro canine pancreatic micro-
somal membrane translation experiment may again be
due to poor 55/57-kDa myocilin doublet resolution or
the inability of this artificial system to faithfully glyco-
sylate myocilin. However, Caballero et al. was able to
detect deglycosylation affects using similar methodology
[20].
Nguyen et al. [10] identified a 66-kDa band as the glyco-
sylated and major extracellular form of human myocilin
and not the upper band in the 55/57-kDa doublet. These
authors claim that the lower band of the unglycosylated
55/57-kDa doublet is due to cleavage of the N-terminal 32
amino acid signal peptide. In our hands, we do not see a
66-kDa band on our anti-myocilin Western blots, even us-
ing human aqueous humor as a source of myocilin. We
provide evidence that the upper band of the 55/57-kDa
doublet is the glycosylated form of myocilin (Fig. 3A). An-
other group has also reported the 66-kDa band using an
anti-myocilin antibody different from the Nguyen et al.
antibody [14]. The reason for the appearance of this 66-
kDa is unclear, but may be due to cross-reaction of the pri-
mary or secondary antibody with another protein such as
albumin, which has a molecular weight of 65-kDa (Gen-
Pept accession # NP_000468). To date, protein sequence
data identifying the 66-kDa band as myocilin has not
been reported.
Human myocilin Asn57 is part of an N-linked glycosyla-
tion consensus (NES) and is the only residue on myocilin
predicted to be N-glycosylated. We provide both site-di-
rected mutagenesis (Fig. 3B) and deglycosylation (Fig. 3A)
evidence that the upper band of the 55/57-kDa human
and monkey myocilin doublet is the glycosylated form.
The increase in mobility of rabbit myocilin with deglyco-
sylation (Fig. 3A) is likely due to removal of O-linked gly-
cosylation. Analysis of O-linked glycosylation by the CBS
NetOGlyc 2.0 Prediction Server http://www.cbs.dtu.dk/
services/NetOGlyc/ identified two unique (rabbit Thr93
and Thr267) and three common (rabbit Thr66, Thr263,
and Ser45) O-linked glycosylation sites in rabbit vs. hu-
man/monkey myocilin. The additional O-linked glyco-
sylation sites in rabbit may be responsible for the mobility
shift seen in the deglycosylation experiment and the rela-
tive diffusiveness of the rabbit myocilin band.
A naturally occuring Asn57Asp polymorphism may be as-
sociated with JOAG [39] which, if truly disease-associated,
would suggest the functional importance of N-linked gly-
cosylation. N-linked glycosylation is known to confer sta-
bility on many extracellular proteins [40]. Myocilin is
similar to fibronectin (an extracellular matrix protein) in
that both a glycosylated and unglycosylated form is secret-
ed from the cell. The unglycosylated form of fibronectin is
more susceptible to proteolytic degradation than the glyc-
osylated form [41]. It will be interesting to determine why
two forms of myocilin are secreted in humans and what
functionality, if any, N-linked glycosylation imparts on
human vs. rabbit myocilin.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/5
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It is still unknown how myocilin functions normally and
pathophysiologically. However, recent evidence suggests
that disease-causing myocilin mutations are gain of func-
tion. Disease-causing myocilin mutants are less soluble in
Triton [16] and are retained by the cell [12]. Other studies
have shown that a truncated form of myocilin does not get
secreted [20,21] and that mouse MYOC  knockouts are
without discernable phenotype [42]. Furthermore, a hu-
man hemizygous individual containing an interstitial de-
letion of chromosome 1, which encodes MYOC, was
without evidence of glaucoma [43] and another patient
homozygous for a severly truncated form of myocilin had
no evidence of glaucoma [44] or other discernable pheno-
types. This suggests that MYOC haploinsufficiency is not
causative for glaucoma and that myocilin may even be
dispensable or redundant in normal human development
or only important when ocular stress occurs.
Conclusions
Rabbit MYOC encodes a protein highly similar to human
MYOC. Rabbit myocilin is secreted and is detected in rab-
bit aqueous humor. Secretion of myocilin is dependent
on an 18 amino acid N-terminal signal peptide. Unlike
human and monkey AH myocilin, rabbit myocilin does
not undergo canonical N-linked glycosylation due to the
substitution of a serine in the analogous human N-linked
glycosylation site (N57). Rabbits may provide an in vivo
system for modeling some aspects of glaucoma, such as
steroid induced ocular hypertension [23–27] and the
gain-of-function hypothesis in POAG [42].
Methods
Cloning of rabbit MYOC
Total RNA was extracted from rabbit eye and heart tissue
(Pel Freez) using Trizol (Invitrogen). Primers derived
from conserved regions of human and mouse MYOC (Ta-
ble 1, primers Exon1F/Exon1R) were used to amplify a
250-bp section of rabbit MYOC exon 1 (Fig. 1, nts 184–
433) by PCR as described [15]. 5' and 3' RACE (Invitro-
gen) was used to obtain the 5' and 3' cDNA ends. Essen-
tially, two micrograms rabbit total RNA was converted
into first strand cDNA with adapter primer and Super-
script II reverse transcriptase. Primary and nested 5' and 3'
RACE primers were all designed within the 250-bp region
of rabbit MYOC exon 1 (Table 1). PCR products were sub-
cloned into TOPO™ TA cloning vectors (Invitrogen) and
subjected to cycle sequencing (Division of Molecular
Transport, Department of Internal Medicine, University of
Texas Southwestern Medical Center).
Due to difficulties in amplifying the rabbit MYOC coding
region from cDNA, we pieced together the entire contigu-
ous open-reading frame using rabbit genomic DNA
(Clontech; New Zealand White) as a template with a mul-
ti-step PCR/ligation process. In the first step, exons 1 and
2 were amplified from genomic DNA with primers P357F/
P368R to exon 1 and P355F/P365R to exon 2. Primers
P368R and P355F directly abut each other at the exon 1/2
boundary. PCR amplification was performed in a 50 ul
volume with the PfuTurbo Hotstart DNA Polymerase sys-
tem (Stratagene) and included 0.2 mM dNTPs, 100 ng
each primer, 2.5 units PfuTurbo DNA polymerase, 100 ng
genomic DNA, and 1X cloned Pfu DNA polymerase reac-
tion buffer. Cycling conditions consisted of 2 min at 95°C
followed by 15 cycles at 95°C 30 sec, 60°C 30 sec, and
72°C 1 min in a Perkin Elmer 9700 thermalcycler. PCR
products were restriction digested with BamH1 (exon 1)
or Not1 (exon 2), purified from an agarose gel by
Qiaquick extraction (Qiagen), and simultaneously sub-
cloned into a BamH1/Not1 digested pcDNA3 (Invitro-
gen) vector to create a directional clone of rabbit MYOC
exons 1 and 2 spliced together (pcDNA3.RbMYOCex1–
2). Sequence integrity of the cloned DNA was verified by
cycle sequencing and restriction digestion.
Exons 1–2 of plasmid pcDNA3.RbMYOCex1–2 was then
amplified with primers P357F/P370R and exon 3 was am-
plified from genomic DNA with primers P356F/P356R.
Primers P370R and P356F directly abut each other at the
exon 2/3 boundary. PCR was performed as above and
PCR products digested with BamH1 (exons 1–2) or Not1
(exon 3) and processed/cloned as above to create a direc-
tional clone of rabbit MYOC exons 1–2 and 3 spliced to-
gether (pcDNA3.RbMYOCex1–3). Plasmid DNA integrity
was confirmed by restriction analysis and cycle
sequencing.
Sequence analysis and comparison
Alignment of DNA sequence contigs, protein sequences,
and plasmid DNA sequence/construction was performed
with Vector NTI 7.1 software (Informax).
Construction of human MYOC mutants
Human MYOC cDNA was cloned into the pcDNA3 (Inv-
itrogen) mammalian expression vector as described [12].
Human myocilin signal sequence deletions were generat-
ed by PCR. A 5' PCR primer, with a 5' HindIII site added,
was designed to eliminate either the first 42- (P235;
∆N14) or 96- (P236; ∆N32) nucleotides of the human
MYOC ORF and used in conjunction with a 3' PCR primer
(P237) covering the internal Bsu36I restriction site (Table
1). Primer P236 replaced the first 32 amino acid codons
with a methionine codon. PCR and processing were as de-
scribed above with the exception that the 5' human
MYOC  deletion products were cloned into a HindIII/
Bsu36I digested pcDNA3.hMYOC wild-type vector.
Substitution of human myocilin Asn 57 with Ser was ac-
complished using the QuickChange XL Site-Directed Mu-
tagenesis kit (Stratagene) according to the manufacturer'sBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/5
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instructions. Primer pair P316F/P316R was designed to
replace the Asn57 AAT codon with the Ser AGT codon (Ta-
ble 1). The entire mutated cDNA was sequence verified
and subcloned into a fresh pcDNA3 vector to avoid non-
specific Taq DNA polymerase errors. Proper cloning was
verified by restriction digestion analysis and sequencing.
Cell culture and transfection
GTM66 cells were derived from a 92-year old woman with
glaucoma and were cultured in low glucose DMEM
(HyClone Laboratories) with 10% FBS (HyClone Labora-
tories) and antibiotics (Invitrogen) as described [11,17].
Cells were transfected with Lipofectamine 2000 reagent
according to the manufacturers recommendations (Invit-
rogen). Transfected plasmid DNA included wild-type hu-
man  MYOC  (pcDNA3.hMYOC; [12]), wild-type rabbit
MYOC (pcDNA3.RbMYOC.ex1–3), N-terminal 14 amino
acid deleted human MYOC (pcDNA3.hMYOC.∆N14), N-
terminal 32 amino acid deleted human MYOC
(pcDNA3.hMYOC.∆N32), or N57S human MYOC
(pcDNA3.hMYOC.N57S). Cells were switched to serum-
free media 24 h post-transfection and media or cell lysates
were collected after overnight incubation. Equivalent cell
lysate protein amounts (5 µg) were loaded for reduced
SDS-PAGE analysis (Fig. 3B). Cell media was not concen-
trated and was loaded at 16 ul per lane in Fig. 3B.
Aqueous humor samples
All experimental animals used in this study were treated in
compliance with the Association for Research in Vision
and Ophthalmology (ARVO) resolution on the use of an-
imals in research. Rabbit aqueous humor samples (135–
190 µl) were taken from anesthetized New Zealand Albi-
no (NZA) rabbits and mixed with protease inhibitor cock-
tail (Complete; Roche) to prevent myocilin degradation.
Human aqueous humor samples were obtained as previ-
ously described [12]. The equivalent of 4 µl AH was used
per lane in Fig. 3A.
Immunoblot analysis
Cells were rinsed with PBS and solubilized in a commer-
cial mammalian extraction buffer (M-Per™; Pierce, Rock-
ford, IL) supplemented with a protease inhibitor cocktail
(Complete; Roche) followed by centrifugation at 12,000 ×
g for 5 min. Protein concentration of the supernatant was
determined with Coomassie Plus Protein Assay Reagent
(Pierce). Cell extracts were stored at -20°C.
Aqueous humor, cell media, and cell extracts were ana-
lyzed using pre-cast Criterion 7.5% Tris-HCl polyacryla-
mide gels (Bio-Rad) and the Bio-Rad electrophoresis
system (Bio-Rad). Proteins were electroblotted to Hy-
bond-P PVDF membranes (Amersham Pharmacia Bio-
tech), blocked with gelatin, and probed with affinity
purified rabbit anti-human myocilin antibody 129
(AB129; generated to human myocilin amino acids 156–
171) [12,17] and an anti-rabbit IgG secondary antibody
(Amersham). Immunoreactivity was detected with the
ECL Plus detection system (Amersham). Blots were ex-
posed to BioMax MR film (Eastman Kodak) and scanned
with a HP ScanJet 7400 c scanner (Hewlett Packard).
Deglycosylation of aqueous humor myocilin
Aqueous humor from human, monkey and rabbit was
subjected to deglycosylation with a mixture of N-linked
and O-linked glycosidases (PNGase F, sialidase, β-galac-
tosidase, glucosaminidase and O-glycosidase) using the
Enzymatic CarboRelease Kit according to the
manufacturers instructions (QA-Bio). AH samples in buff-
er were boiled for 5 min in the presence of denaturant fol-
lowed by incubation for 3 hr at 37°C with the glycosidase
mixture. NuPAGE sample buffer (Invitrogen) was added
to stop the reaction, samples were heated for 10 min at
70°C and subjected to NuPAGE electrophoresis on 10%
NuPAGE gels (Invitrogen). Samples were transferred to
PVDF, immunoblotted versus AB129, and developed us-
ing ECL Plus.
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